Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07347379

Enrollment

108

Registered

2026-01-16

Start date

2025-11-13

Completion date

2026-12-01

Last updated

2026-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aphakia Cataract

Keywords

Light Adjustable Lens LAL Intraocular lens

Brief summary

This is an observational, follow up study of subjects previously enrolled in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study". The primary objective of this study is to collect long-term safety and effectiveness data on RxSight LAL in subjects previously implanted in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study".

Interventions

DEVICELight Adjustable lens (LAL) and Light Delivery Device (LDD)

Experimental treatment group received Light adjustable lens with Light delivery Device treatments

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Subject and study eye with prior participation in the CSP-029 study and implanted with the LAL.

Exclusion criteria

* Subjects with serious co-morbid conditions that in the judgment of the investigator makes inclusion in the study not in the best interest of the subject.

Design outcomes

Primary

Measure	Time frame
Mean absolute manifest refraction spherical equivalent (\|MRSE\|) at the Long-Term follow up visit	Up to 55 months
Mean manifest cylinder at the Long-Term follow up visit	Up to 55 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 13, 2026